CureVac N.V.
CVAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.30 | 0.11 | -0.11 |
| FCF Yield | 11.29% | -38.47% | -35.63% | -15.34% |
| EV / EBITDA | 1.41 | -2.05 | -2.92 | -12.50 |
| Quality | ||||
| ROIC | 20.52% | -45.22% | -35.16% | -51.18% |
| Gross Margin | 80.23% | -131.34% | -172.91% | -131.28% |
| Cash Conversion Ratio | 0.53 | 1.03 | 1.15 | 1.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 99.48% | -19.48% | 11.30% | 80.83% |
| Free Cash Flow Growth | 125.82% | 14.84% | 55.94% | -281.25% |
| Safety | ||||
| Net Debt / EBITDA | -2.11 | 1.54 | 2.17 | 2.02 |
| Interest Coverage | 0.00 | -109.99 | -67.29 | -39.88 |
| Efficiency | ||||
| Inventory Turnover | 195.62 | 5.01 | 7.67 | 4.24 |
| Cash Conversion Cycle | -35.26 | 200.08 | -39.06 | 89.15 |